

Asterand Board Change

Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announced that Ian Ratcliffe, one of Asterand's non-executive Directors, intends to step down from the Board at Asterand's AGM on the 8th of June 2010.

Mr. Ratcliffe, an Independent Director since May 2008, is currently President and CEO of Stemgent, Inc. (Boston, MA, USA), a life science company focused on the development and sale of novel consumable reagents for use in stem cell research. Mr. Ratcliffe noted the possibility of appearance of potential conflict of interest.

Jack Davis, Asterand's Chairman, said "Ian has proven to be an asset to our company and has contributed significantly to our success during his tenure on our Board. However, with the rapid pace of technological change seen in our industry, we understand the concern about possible conflict of interest. Ian's deep industry experience, entrepreneurial spirit and practical counsel will be missed, and we wish him well for the future."

Contacts:

Asterand plc

Martyn Coombs, Chief Executive Officer

Tel: + 44 (0) 1763 211 600 /
+ 1 (313) 263-0960

Jack Davis, Chairman

As above

Buchanan Communications

Lisa Baderoon / Mark Court / Jennie Spivey

Tel: +44 (0) 20 7466 5000

Cenkos Securities plc

Stephen Keys / Beth McKiernan

Tel: + 44 (0) 20 7397 8924

Daniel Stewart & Company plc

Martin Lampshire

Tel: +44 (0) 20 7776 6550

About ASTERAND

Asterand plc is a leading supplier of high quality human tissue and tissue-based research services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market.

For more information on Asterand, go to www.asterand.com